What changed
$ZLAB — ADD 📊 | 6 MONTHS THESIS
🎯 latest | Rev $38M | EPS $-0.46 vs $-0.53 🟢
💡 Consensus models a gradual profitability inflection in 2026–2027, but the beat magnitude and cost discipline suggest a break-even quarter is plausible by late 2025, pulling forward the timeline.
📉 Reward/risk: 2.1:1
🏢 Business Quality: 6/10 - Diversified in-licensed oncology portfolio with solid revenue growth, but heavily dependent on partners and exposed to Chinese regulatory and competitive risks.
📊 Valuation: Fair: EV/2024E Sales ~3x is inexpensive for ~20% revenue growth and margins improving, but in line with Chinese biotech peers given policy...
🔮 Catalyst: Post-earnings analyst estimate revisions and guidance raise during Q1 2025 quiet period communications
💰 Entry: $18.18, stop $15.0, target $25.0
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/ZLAB0621